Robert E. Reiter, MD, MBA, Author at Grand Rounds in Urology

Robert E. Reiter, MD, MBA

Geffen School of Medicine at UCLA

Los Angeles, California

Robert E. Reiter, MD, MBA, is the Bing Professor of Urology and Molecular Biology and Director of the Prostate Cancer Treatment and Research Program at the David Geffen School of Medicine at the University of California, Los Angeles. He is currently the Principal Investigator of UCLA’s SPORE (Specialized Program in Research Excellence) program, a $12 million research grant from the National Cancer Institute to develop new diagnostic and treatment options for men with prostate cancer. Dr. Reiter’s clinical interests include robotic surgical management of prostate cancer and the use of both MRI and molecular imaging tools to manage this disease. His research is focused on the development of novel antibodies for both treatment and imaging of prostate cancer, as well as on the role of epithelial to mesenchymal transition in castration and treatment resistance. Dr. Reiter completed his undergraduate studies at Yale University and earned his medical degree at Stanford University Medical School.

Disclosures:

Talks by Robert E. Reiter, MD, MBA

The Ups and Downs of MRI Interrogation of the Gland

Posted by Robert E. Reiter, MD, MBA | Mar 2018

Robert Reiter, MD, discusses the uses of MRI in prostate cancer management, especially its ability to predict biochemical recurrence (BCR). He also explains the difference between mapping and targeted biopsies, and how MRI suspicion score and tumor volume are associated with grade, stage, and recurrence of disease.

Robert E. Reiter, MD, MBA

Geffen School of Medicine at UCLA

Los Angeles, California

Talks by Robert E. Reiter, MD, MBA

The Ups and Downs of MRI Interrogation of the Gland

Join the GRU Community

You have Successfully Subscribed!